Medical Isotope Potential
A 14 MeV source can reach production routes for certain medical and research isotopes — a potential service, stated cautiously and without economics.
A potential, framed honestly
The medical-isotope supply chain depends heavily on a small number of aging fission reactors, and shortages of key diagnostic and therapeutic isotopes have been a recurring problem. A fusion neutron source offers alternative production routes, particularly for isotopes best reached by fast or threshold reactions that fission spectra do not favor.
Kronos states this as a potential, not a committed product. Realizing medical-isotope production requires target chemistry, hot-cell processing, radiochemical purification, and stringent regulatory qualification for medical use — a substantial program beyond simply having neutrons. The physics capability is real; the pathway to certified medical product is long.
Why a fusion source is interesting here
- Threshold (n,2n)/(n,p) routes can yield high-specific-activity products
- Carrier-free production for some isotopes via specific reactions
- Diversifies supply away from a fragile fission-reactor base
- Complements activation and neutron-services offerings
Honest limits
No medical isotope is claimed as a deliverable of Hyperion today. The machine is an engineering program, and any medical-isotope service would follow its own qualification and licensing path well after FOAK. This page describes physical potential only and makes no commercial claim of any kind.
Construction begins Q2 2027; first-of-a-kind (FOAK) first tritium is targeted near 2030. No net-gain claim is made before FOAK.